Ascentage Pharma Group International
NASDAQ:AAPG · NASDAQ Global Market
+$0.31 today
Vol 0.01M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-91.2%
avg -144.0%
ROIC
-33.3%
avg -33.0%
ROA
-30.5%
avg -36.9%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -36.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dajun Yang | Co-Founder, Chairman & Chief Executive Officer | $6.07M | — | 63 | $0.00 | <0.01% |
Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | $237,568.00 | — | 61 | $0.00 | <0.01% |
Manish Tandon | SVP of Business Development | — | — | — | — | — |
Chongdong Fu | Senior Vice President & Head of CMC | — | — | — | — | — |
Veet Misra | Chief Financial Officer | — | — | — | $18,584.00 | 0.08% |
Yifan Zhai | Chief Medical Officer | — | — | 63 | $1.19M | 5.14% |
Zhichao Si | Head of Commercial | — | — | — | — | — |
Eric Huang | Senior Vice President of Global Corporate Development & Finance | — | — | — | — | — |
Jin Cao | Head of Finance | — | — | 40 | $5,400.00 | 0.02% |
Thomas Joseph Knapp | Senior Vice President & General Counsel | — | — | 73 | $362,444.00 | 1.56% |
Yuly Chen | Senior Director of Investor Relations | — | — | — | — | — |
Ming Guo | Co-Founder | — | — | 68 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +25.3% | +82.9% (10yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +25.3% over three years. Forward estimates point to Revenue at +82.9% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.44B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.35B
Legend Biotech Corporation
NASDAQ:LEGN
$5.34B
Celcuity Inc.
NASDAQ:CELC
$4.20B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.72B
Disc Medicine, Inc.
NASDAQ:IRON
$2.68B
Zai Lab Limited
NASDAQ:ZLAB
$2.06B
Who manages AAPG?
Ascentage Pharma Group International (AAPG) lists 12 active executives. The top listed executive is Manish Tandon, SVP of Business Development.
Are AAPG insiders buying or selling?
Recent insider activity shows net buying of $8.43M.
Explore More
Continue the stock analysis
Jump to another research area for this company.